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Background: Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive
disorder of the urea cycle. HHH has a panethnic distribution, with a major prevalence in Canada, Italy and Japan.
Acute clinical signs include intermittent episodes of vomiting, confusion or coma and hepatitis-like attacks. Alternatively,
patients show a chronic course with aversion for protein rich foods, developmental delay/intellectual disability,
myoclonic seizures, ataxia and pyramidal dysfunction. HHH syndrome is caused by impaired ornithine transport
across the inner mitochondrial membrane due to mutations in SLC25A15 gene, which encodes for the mitochondrial
ornithine carrier ORC1. The diagnosis relies on clinical signs and the peculiar metabolic triad of hyperammonemia,
hyperornithinemia, and urinary excretion of homocitrulline. HHH syndrome enters in the differential diagnosis with
other inherited or acquired conditions presenting with hyperammonemia.
Methods: A systematic review of publications reporting patients with HHH syndrome was performed.
Results: We retrospectively evaluated the clinical, biochemical and genetic profile of 111 HHH syndrome patients,
109 reported in 61 published articles, and two unpublished cases. Lethargy and coma are frequent at disease
onset, whereas pyramidal dysfunction and cognitive/behavioural abnormalities represent the most common clinical
features in late-onset cases or during the disease course. Two common mutations, F188del and R179* account
respectively for about 30% and 15% of patients with the HHH syndrome. Interestingly, the majority of mutations
are located in residues that have side chains protruding into the internal pore of ORC1, suggesting their possible
interference with substrate translocation. Acute and chronic management consists in the control of hyperammonemia
with protein-restricted diet supplemented with citrulline/arginine and ammonia scavengers. Prognosis of HHH
syndrome is variable, ranging from a severe course with disabling manifestations to milder variants compatible
with an almost normal life.
Conclusions: This paper provides detailed information on the clinical, metabolic and genetic profiles of all HHH
syndrome patients published to date. The clinical phenotype is extremely variable and its severity does not correlate
with the genotype or with recorded ammonium/ornithine plasma levels. Early intervention allows almost normal
life span but the prognosis is variable, suggesting the need for a better understanding of the still unsolved
pathophysiology of the disease.
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Hyperornithinemia-hyperammonemia-homocitrullinuria
(HHH, MIM #238970) syndrome is a rare genetic dis-
order of the urea cycle (UC) caused by mutations in the
SLC25A15 or ORNT1 gene (MIM*603861), which en-
codes for the mitochondrial ornithine carrier ORC1 [1].
HHH syndrome represents a heterogeneous disease with
high clinical variability, ranging from a mild form with
learning difficulties and slight neurological involvement,
to a more severe form with coma, lethargy, hepatic signs
and seizures. Asides from the severe neonatal form,
there is no evidence of a direct correlation between age
of onset, which is variable, and disease severity [1]. As
for other urea cycle disorders (UCDs), early diagnosis in
infancy or childhood may improve the clinical outcome
[1]. Acute treatment requires an emergency approach,
whereas the long-term treatment consists of a low-
protein diet supplemented with citrulline or arginine; in
some patients, sodium benzoate and/or sodium phenyl-
butyrate are used to maintain blood ammonia in a safe
range [1]. In this paper, we aim to provide a comprehensive
review of the genetic and molecular aspects of HHH
syndrome, a descriptive picture of clinical features and
therapeutic strategies along with a discussion on the still
unsolved questions related to the disease pathomechanisms.
History and disease definition
In 1969, Shih et al. described a 3 years-old boy with cog-
nitive impairment and myoclonic seizures, in whom
intermittent hyperammonemia was associated with ab-
normal high plasma ornithine levels and homocitrullinuria
[2]. These authors coined the name “hyperornithinemia-
hyperammonemia-homocitrullinuria (HHH) syndrome”
(Orpha number 415) to describe the peculiar biochemical
profile, suggestive of a “block in the ornithine metabolic
pathway”.
Epidemiology
Since the original description [2-4], more than 100 patients
with HHH syndrome have been reported [5-61]. Overall,
according to a recent survey based on newborn screening
data on over 6 million births in United States (US) and data
from two large US and European longitudinal registries, the
incidence of all UCDs is estimated as 1:35.000 live births
[62]; however figures reporting the incidence of HHH
syndrome are still lacking. Based on the few available large
series studies on UCDs, HHH syndrome accounts for
1% – 3,8% of all UCDs [62,63]. On the basis of the available
information in the literature for 97 out of 111 patients
[5-61] the male/female ratio is approximately 2:1 (Table 1).
Methods
We retrieved clinical and investigational data on HHH
syndrome patients published to date. The PubMed databasewas searched using the terms: “HHH syndrome; Hyper-
ornithinemia; Hyperammonemia; Homocitrullinuria;
ornithine carrier; ORC1; ORNT1; urea cycle disorders;
SLC25A15”. The terms were variably combined with:
“early onset, infancy-childhood onset; adult onset, late
onset, review, case, case series”. In addition, references
listed in the papers retrieved by this method as well as
in the textbook “The Metabolic and Molecular Bases of
Inherited Diseases” [64] were screened, along with a
reference list started in 1985 by the last author of this
work. Data on clinical symptoms and biochemical and
genetic data were pooled for analysis whenever the
description of the cases allowed. The individual relevant
data obtained from the literature were used to create a
database that is reported in Table 1 and in Additional
file 1: Table S1. We additionally included data from two
unreported patients, recently diagnosed and managed at
Children’s Research Hospital Bambino Gesù, Rome,
Italy (patients 110 and 111); written informed consent
was obtained from the caregivers of these two patients
for publication of their clinical and biochemical data.
Patients n. 10, 19, 25, 49, 51, 52, and 94 were monitored
longitudinally in the same institution.
Results
Ethnic distribution
Although the disease has a panethnic distribution, it has
been more frequently reported in three countries: 25
patients (23%) were Canadian, as a result of a founder
mutation in Quebec [37], 18 patients (17%) were Italian
and 14 patients (13%) were Japanese. Therefore, these
three countries account for more of 50% of affected
cases. The complete list of patients’ ethnic background
is displayed in Table 1.
Clinical description
Age at onset, type and severity of the symptoms in HHH
syndrome are highly variable. Clinical symptoms usually
start from early infancy, including the neonatal period,
to childhood and, more rarely, in adulthood.
Age at onset and diagnosis
The retrospective review of the literature provided in-
formation on the age at onset in 54 HHH syndrome
patients and on the age at diagnosis in 105 subjects
(Table 1), whom we arbitrarily divided into four categories:
neonatal (birth – 1 month), infantile (>1 month – 1 year),
childhood (>1 years – 12 years), and adolescence/adult-
hood (>12 years). In 14 patients there was a prospective
diagnosis, because of an affected sibling or previous
familial HHH syndrome cases; only one patient was
identified by newborn screening. Figure 1 shows the
percentage of patients grouped into the four categories
at onset and at diagnosis, respectively. As shown in the
Table 1 The table summarizes relevant clinical features and molecular findings in 111 patients with HHH syndrome
























1,1 1,5 43,0 Yes No Yes No 1 Yes Yes 915 p.A264P/p.F188del [2-4]
2 f English 2,5 21,0 23,0 Yes Yes No No 3 Yes Yes 1021 [5,6]
3 m French
Canadian
0,8 7,0 9,0 Yes Yes Yes Yes 3 Yes Yes 372 [7-12]
4 m French
Canadian
1,9 2,0 5,0 Yes Yes 3 Yes Yes 330 [7,9,11]
5 f French
Canadian
47 17,0 Yes No 1 No No 380 [7,11]
6 m French
Canadian
31,0* 31,0 No No 3 Yes 519 [7]
7 f French
Canadian
22,0* 22,0 yes No No No No 430 [7]
8 m French
Canadian
18,0* 19,0 No No Yes+ 3 No No 483 [7]
9 f NA 4,0 6,5 No No Yes No No No No 410 [13]
10 f Italian 0,2 0,8 1,0 Yes No No 1 Yes Yes 689 [14]
11 m NA 1,4 2,5 4,7 Yes No No 3 Yes No 229 [9]
12 m Italian 1,1 2,5 Death 2,5 Yes Yes Yes+ Yes+ Yes 797 [15]
13 m Italian 0,8 2,6 3,6 Yes No No No Yes 1041 [15]
14 m Japanese 42,0 46,0 Yes Yes No 700 [16]
15 m NA 5,5 8,0 No No No No 3 Yes Yes 586 [17]
16 m NA No 1014 [18]
17 m NA 4,2 10,7 1 [18]
18 m Norwegian/
Yugosl-Italian
0,4 1,1 4,0 No No Yes+ Yes No No No 887 [19]
19 f Italian Birth 0,2 20,0 Yes Yes Yes Yes No No Yes 618 p.G27R/p.G27R [20-23]
20 m Japanese 13,0* 13,0 No No No No 1 Yes Yes 409 [24]
21 m Japanese 4,0 19,0 19,0 Yes No No No 3 Yes Yes 477 [24]
22 m Spanish 9,0 21,0 21,0 No No 3 No Yes 719 [25]
23 f Spanish 18,0 18,0 No No 3 No Yes 780 [25]














Table 1 The table summarizes relevant clinical features and molecular findings in 111 patients with HHH syndrome (Continued)
25 m Italian Birth 2,0 21,0 Yes Yes Yes No 3 Yes Yes p.Ser90*/p.Ser90* [21-23]
26 m Japanese 3,0 10,0 10,0 Yes No No No 3 No Yes 419 p.R179*/p.R179* [26,27]
27 f Japanese 37,0 504 [28]
28 m Japanese 11,0 879 [28]
29 m Japanese 19,0 553 [28]
30 f 20,0 24,0 Yes Yes 860 [29]
31 m Japanese 17,0 17,0 Yes No 3 Yes Yes 834 p.229_230insN/
p.229_230insN
[30,31]
32 m 37,0 39,0 Yes Yes Yes Yes No No Yes 310 [32]
33 f 40,0* 42,0 Yes No No 263 [32]
34 m Japanese 35,0 41,0 Yes Yes No 1 No Yes 586 p.R179*/p.R179* [31,33]
35 m Japanese 15,0 16,0 No No 3 No Yes p.G27E/p.G27E [31,34]
36 m French
Canadian
Birth Birth Death Birth Yes Yes Yes 1915 [35]
37 m French
Canadian
1,2 21,0 No No Yes Yes 1 No Yes 727 p.F188del/p.F188del [36-38]
38 f French
Canadian
5,3 22,0 No No Yes Yes 1 No Yes 343 p.F188del [36-38]
39 f French
Canadian
1,3 25,0 No No Yes Yes 1 No Yes 1083 p.F188del/p.F188del [36-38]
40 m French
Canadian
12,0 33,0 No No No No 3 No Yes 515 p.F188del/p.F188del [36-38]
41 m French
Canadian
3,5 35,0 No No Yes+ No 3 No Yes 606 p.F188del/p.F188del [36-38]
42 m French
Canadian
8,0 40,0 Yes Yes Yes Yes+ 3 Yes Yes 700 p.F188del/p.F188del [36-39]
43 f French
Canadian
3,5 5,5 6,5 No No Yes Yes 1 No Yes 470 [40]
44 NA 0,6 0,6 3 577 [41]





















Table 1 The table summarizes relevant clinical features and molecular findings in 111 patients with HHH syndrome (Continued)
49 m Italian 12,0 26,0 28,0 Yes No No Yes 1 Yes Yes p.R179*/p.R179* [22,23]
50 m Italian 18,0 21,0 29,0 Yes Yes Yes+ No 1 Yes Yes 505 (IVS5 + 1 g > a/IVS5 +
1 g > a) exon skipping
[22,23]
51 f Italian 3,0 7,0 24,0 Yes Yes No No 2 Yes Yes 780 p.R275Q/p.R275Q [22,23,44]
52 f Italian 1,0 33,0 44,0 3 Yes p.Q89*/p.Q89* [22,23]
53 m Italian Birth Birth 23,0 Yes Yes No Yes Yes p.F188del/p.G190D [22,23]
54 f NA 5,0 17,0 32,5 No No No 3 No Yes 312 [45]
55 m NA 13,0 15,0 15,0 No No 3 No 520 [45]
56 f NA 0,8 0,8 No No No 1 No No [46]
57 f Japanese 52,0 52,0 No No No No No Yes Yes 373 p.R179*/p.R179* [27,47]
58 m Slovakian 1,6 10,0 No No Yes+ No No 425 p.G113C [48]
59 m Japanese 1,5 15,0 15,0 No No No 3 No Yes 682 p.P126R/p.P126R [49]
60 m Palestinian 1,8 1,8 No Yes No 3 Yes No 532 p.L193*/p.L193* [50]
61 m Palestinian 13,0* 13,0 No No No 3 Yes No 314 p.L193*/p.L193* [50]
62 f Japanese 2,0 30,0 30,0 No 2 Yes Yes 373 p.R275*/p.R275* [51]
63 m Japanese 3,0 34,0 Death 34,0 Yes Yes 3 Yes Yes p.R275*/p.R275* [51]
64 m Italian 3,5 3,5 3,5 Yes No Yes+ Yes+ No No No 852 p.G113C/p.M273K [52]
65 m Mexican 5,0* 9,0 No Yes+ Yes No No No 697 p.T32R/p.T32R [53]
66 f Mexican 13,0 18,0 No No No No 353 p.T32R/p.T32R [53]
67 m Mexican 8,0 Death 21,0 Yes Yes 3 No Yes 386 p.T32R/p.T32R [53]
68 m Mexican 7,0* 20,0 No No No No 371 p.T32R/p.T32R [53]
69 m Mexican 3,0* 15,0 No No No No 370 p.T32R/p.T32R [53]
70 m NA Birth 0,1 3,0 Yes 3 616 [54]
71 f French-
Canadian
1,0 1,1 1,1 Yes No Yes+ Yes+ No No No 933 p.F188del/p.F188del [55]
72 f French-
Canadian
1,2 1,2 1,2 No No Yes+ Yes+ No No No 580 p.F188del/p.F188del [55]
73 f Saudi arabia 1,0 1,5 4,0 No No Yes+ Yes+ 3 No Yes 465 p.G220R/p.G220R [56]
74 Saudi arabia 13,0* 13,0 No No 1 No Yes 590 p.G220R/p.G220R [56]
75 Saudi arabia 7.0* 7,0 No No 1 No Yes 493 p.G220R/p.G220R [56]
76 French
Canadian
1,0 14,0 No No Yes+ Yes+ No Yes 642 p.F188del/p.F188del [38]
77 French
Canadian














Table 1 The table summarizes relevant clinical features and molecular findings in 111 patients with HHH syndrome (Continued)
78 French
Canadian
2,4 9,0 No No Yes+ Yes+ No Yes 310 p.F188del/p.F188del [38]
79 French
Canadian
0,2** 7,0 No No No No No Yes 397 p.F188del/p.F188del [38]
80 French
Canadian
2,0 6,0 No No Yes No No Yes 337 p.F188del/p.F188del [38]
81 French
Canadian
15,0 29,0 Yes Yes No Yes Yes Yes 431 p.F188del/p.F188del [38]
82 French
Canadian
16,0 Death 23,0 Yes Yes Yes No Yes 227 p.F188del/p.F188del [38]
83 French
Canadian
2,0 31,0 No No No Yes 581 p.F188del/p.F188del [38]
84 French
Canadian
3,0 17,0 No No No Yes 529 p.F188del/p.F188del [38]
85 French
Canadian
1,5 5,0 No No Yes No Yes 348 p.F188del/p.F188del [38]
86 m Belgium 0,3 0,7 6,0 No No Yes Yes 1 No No 951 p.M37R/p.M37R [57]
87 f Italian Birth 0,2 Death 0,2 Yes No No No No No p.L71Q/p.L71Q [57]
88 m Algerian 2,0 5,0 No No No 3 No Yes 885 p.K245*/p.K245* [57]
89 m Algerian Birth Birth* 3,0 No No No 3 No Yes 887 p.K245*/p.K245* [57]
90 f Senegal Birth Birth 6,0 Yes Yes No Yes+ 1 Yes Yes 509 p.R179*/p.R179* [57]
91 f Senegal Birth Birth 6,0 Yes No No No 1 No Yes 290 p.R179*/p.R179* [57]
92 m Spanish 2,0 2,0 3 419 p.G216S/p.G216S [57]
93 f Taiwan 1,1 2,0 2,0 Yes Yes Yes+ Yes+ 450 p.T272I/p.T272I [57]
94 m Italian 41,0 41,0 Yes Yes No Yes No No Yes 216 p.G27R/p.G27R [57]
95 m Italian 24,0 54,0 54,0 Yes No Yes+ Yes No No Yes 603 (c.56 + 1G > T/intronic
change) exon skipping
[57]
96 f USA-Greece Birth Birth 0,1 Yes Yes No Yes No 370 p.S175fsX192/p.L283F [57]
97 m Morocco 1,2 1,5 Yes Yes+ Yes+ 1 No Yes 700 p.A70L/p.A70L [57]
98 f Pakistan 1,0 5,0 No No Yes No 3 No No 471 p.F188L/p.F188L [57]
99 m Morocco 1,7 1,7 2,0 Yes No Yes+ Yes No No No 493 p.R179*/p.R179* [57]
100 m Morocco 4,0* 4,0 p.R179*/p.R179* [57]
101 f Pakistan 20,0 57,0 57,0 Yes Yes No No No Yes Yes p.A70L/p.A70L [57]














Table 1 The table summarizes relevant clinical features and molecular findings in 111 patients with HHH syndrome (Continued)
103 f French
Canadian
2,0 15,0 57,0 Yes Yes Yes Yes Yes 542 p.F188del/p.A264P [4]
104 f El Salvador 4,4 4,5 Death 31,0 Yes No Yes+ Yes 2 Yes Yes 521 p.M33Qfs*1/M33Qfs*1 [4]
105 f Vietnam 1,0 5,0 29,0 Yes Yes Yes Yes 2 Yes Yes 1439 p.R179*/p.R179* [4]
106 m Italian 6,0 36,0 36,0 Yes Yes 309 p.F188del/p.L193P [59]
107 m Turkish 3,5 6,0 9,0 Yes No No No No 380 p.A15V/p.A15V [60]
108 m Han Chinese 1,0 2,0 6,0 No No Yes Yes No No No 503 p.R179*/p.T272I [61]
109 m Han Chinese Birth* 3,0 No No No No No No No p.R179*/p.T272I [61]
110 f Italian 1,0 8,0 8,0 No No Yes No 1 No Yes 427 p.G27R/p.R275G Unp.
111 f Italian 1,0 4,0* 4,0 No No No No No No Yes 531 p.G27R/p.R275G Unp.














Figure 1 The graph shows the age at onset (white bars) and the age at diagnosis (gray bars) of HHH syndrome patients. Patients are
divided into four age categories: neonatal (birth —1 month) infantile (> 1 month—1 year), childhood (> 1 years— 12 yrs), and adolescence/
adulthood (> 12 years). Values are expressed as percentage of the total.
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44% manifested the disorder in childhood, and 9%
in adolescence/adulthood. Although symptoms began
most frequently in neonatal age/infancy (46% of pa-
tients), the diagnosis was often delayed with at least one
fourth of cases identified in adulthood. Remarkably, in
one third of patients with neonatal onset of symptoms,
the diagnosis was delayed into subsequent diagnostic
age categories. By comparing the age at onset of the
clinical symptoms with the age of diagnosis for those
cases in which both these data were available, there was
a mean diagnostic delay of 6.3 ± 10.1 years (range 0 –
37 years).
Acute presentation
As seen in other UCDs [1], in the acute phase the HHH
syndrome combines hyperammonemia with tachypnoea,
respiratory alkalosis, feeding and gastrointestinal prob-
lems, ataxia, lethargy, confusion, and coma. About 1/3 of
patients experienced an overt episode of coma and many
others had recurrent episodes of lethargy (Figure 2). Coma
and lethargy at onset are quite common in the earlier
onset group (about 70%), becoming progressively less
frequent in patients with later onset. Variable neuro-
logical symptoms may characterize the acute presen-
tation and include seizures, dysphasia, movement and
gait disturbances, drop-attacks and behavioural changes
[38,57,58].
As shown in Figure 2, HHH syndrome may also ex-
hibit as fulminant liver failure with severe coagulation
abnormalities (e.g. subdural hematoma, gingival bleed-
ing, melena) and/or as hepatitis-like attacks [15,23,
25,35,37,38,50,52,57]. Remarkably, in some cases massive
elevation of transaminases, with or without signs of acute
liver failure (i.e. coagulation abnormalities with prolongedprothombin time), occurred in the absence of overt hyper-
ammonemia [15,38,53,55,57].
Chronic presentation
HHH syndrome may also present a more chronic and
slowly progressive course, characterized by an aversion to
protein-rich foods, progressive encephalopathy with men-
tal regression and signs of motor dysfunction (Figure 2).
Affected patients in the late-onset categories come to
medical attention mainly for evaluation of intellectual dis-
ability (ID), recurrent vomiting or neurological findings
like ataxia and seizures.
Neurological complications
The peculiar feature of HHH syndrome is a progressive
neurological dysfunction characterized by pyramidal
tract signs with spastic gait, associated with cerebellar
symptoms and myoclonic seizures [23,36,38]. Regardless
of the age and type of onset, pyramidal dysfunction has
been reported in about 2/3 of patients (Figure 2). This
feature can vary from lower limb hyperreflexia with
positive Babinski sign, with or without gait abnormal-
ities, to a clear picture of spastic paraparesis. Cerebellar
signs include ataxia, poor hand and fine motor coordin-
ation, dysdiadochokinesia, dysarthria, nystagmus and
intentional tremor [4,23,36,38]. Other neurological signs
include muscle weakness, involuntary hand movements,
buccofaciolingual dyspraxia and psychiatric disorders.
Seizures, mainly myoclonic, are present in 35% of pa-
tients (Figure 2) and seem to be more frequent in those
with an earlier onset of the disease [4,14,51,59].
Cognitive impairment is also often reported in this dis-
order, and may range from major developmental delay
to variable degree of ID [23,36,38]. Independently from
the age of onset, a greater proportion of patients (74%)
Figure 2 The graph shows the frequency of clinical features in HHH syndrome. For Intellectual disability we identified two categories:
mild (lQ/DQ50-69)/modarate (IQ/DQ35-49) [white bars], and serve (IQ/DQ < 35) [gray barsj. A similar classification was adopted for hepatopathy
[mild/moderate up to 10×) or serve (>10×) increase of trans saminases] and coagulopathy [mild:nioderate individua coagulation factors 40%-70%,
INP 1.5-2.0) or serve (individuaI coagulation factors <40%, INP > 2.0 or related clinical Manifestations) abnormalities of prothromibin time and INR).
Martinelli et al. Orphanet Journal of Rare Diseases  (2015) 10:29 Page 9 of 17presented with cognitive defect, being mild/moderate in
36% and severe in 38% of patients, respectively (Figure 2).
A normal intellectual development was recorded in 29
out of 86 patients (34%). However, some patients with
normal cognitive development displayed behavioral
problems [15,32]. The degree of ID doesn’t seem to be
proportionally related either to the frequency of lethargy/
coma episodes or to ammonium or ornithine concentra-
tions in plasma, as suggested in literature [38]. Additional
clinical features more rarely reported in some HHH
syndrome patients include dysmorphic features, cere-
bral dysplasia [5,6,46] and microcephaly [14,57].
Ocular findings
Retinal involvement, with photophobia, hemeralopia,
tapetoretinal degeneration, cataract and abnormal elec-
troretinogram has also been reported [37,38,44].
Aetiology
Biochemical derangement and pathophysiology
The biochemical role of ORC1 is complex and highly
relevant for the different tissues where it is expressed.
ORC1 transports ornithine, lysine and arginine into the
mitochondrial matrix of peripheral tissues and pericen-
tral hepatocytes; in periportal hepatocytes, in which UC
enzymes are expressed, it catalyzes a very efficient orni-
thine/citrulline exchange reaction [65], connecting the
enzyme activities of urea synthesis in the cytosol to
those in the mitochondria. ORC1 plays therefore a key
role in the UC (Figure 3). ORC1 catalyzes the transport
of the L-isomers of ornithine, citrulline, lysine and argin-
ine by a 1:1 substrate exchange reaction and less effi-
ciently exchanges a basic amino acid for an H+ [65-67].Two human isoforms of the mitochondrial ornithine
carrier, ORC1 and ORC2, have been identified so far.
Despite having a high sequence identity (87%) with
ORC1, ORC2 is less active, presents a lower affinity for
ornithine and citrulline, and shows a broader substrate
specificity because of its capability to transport histidine
and homocitrulline as well as the D-isomers of orni-
thine, lysine and arginine [68]. Both isoforms are mainly
expressed in liver, pancreas, lungs, and testis, although
ORC2 to a much lesser extent than ORC1 in all tissues
investigated [68]. The total mitochondrial ornithine/
citrulline exchange activity per whole organ in vivo is
unknown; it has been suggested that the late onset and
the variable clinical phenotype of HHH syndrome may
be due to the redundancy of this exchange activity
[8,37]. This is catalyzed either by ORC2 [68] or by the
SLC25A29 gene product (previously reported to be a
mitochondrial carnitine/acylcarnitine- or ornithine-like
carrier called ORNT3 [69]), which is able to rescue the
ornithine metabolism deficiency in fibroblasts of HHH
patients [69,70] and to transport basic amino acids as
well as ornithine into proteoliposomes [71]. The re-
sidual ornithine transport in cultured fibroblasts and
liver of affected individuals supports this hypothesis of
gene redundancy in HHH syndrome [8,37].
ORC1 deficiency reduces the mitochondrial availability
of ornithine, which increases in the cytosol causing
hyperornithinemia. The accumulation of ornithine in
cytosol leads also to increased levels of polyamines as
spermine and spermidine [72]. In the periportal zone of
the liver lobuli, the lower level of mitochondrial orni-
thine reduces the UC rate since the matrix ornithine is
required by the ornithine transcarbamylase (OTC) to
Figure 3 The urea cycle and related patwhays. The acronyms correspond to: NAGS, N-acetylglutamate synthase; CPS, carbamyl-phosphate
synthetase; OTC omithine transcarbamylase; ORC1, ornithine carrier 1; ASS argininosuccinate synthetase; ASL argininosuccinate lyase; NOS, nitric oxide
synthase: ODC ortnithine decarboxylase; AGAT, argine: glycine amidinotransferase; GAMT, guanidinoacetate N-methyltransferase; OAT, ornithine delta-
aminotransferase; P5CD 1- pyrrolin-e5-carboxylate dehydrogenase; P5CS, 1-pyrroline-5 carboxylate synthetase; P5CR,1-pyrroline-5-carboxylate reductase;
PO, proline oxidase. The dashed circle indicates the multiprotien complex, which also includes cationic aminoacid transporter 1 (CAT1) and heat shock
protein 90 (HSP 90).
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levels increase, explaining hyperammonemia. Increased
CP may have two destinations: it may bind lysine, for-
ming homocitrulline which gives rise to homocitrullinuria
or enter in the pyrimidine pathway, leading to increased
excretion of orotic acid in urine (Figure 3). Plasma
glutamine is taken up from the systemic circulation into
the gut and then processed to glutamate, pyrroline-5-
carboxylate, ornithine and citrulline. As the liver extracts
only a small quantity of citrulline, this aminoacid is mainly
transported to the kidney and metabolized to arginine in
the tubules of the cortical zone and used for guanidino
acetate synthesis by arginine-glycine amidotransferase
(AGAT), the first step of creatine synthesis, with ornithine
as by-product [73]. In ORC1 deficiency, the high cytosolic
ornithine concentrations inhibit AGAT leading to se-
condary creatine deficiency [21,44,74]. Secondary creatine
deficiency may be also due to low cellular arginine avail-
ability due to the block in UC flow. Moreover, ornithine
excess may inhibit creatine biosynthesis as observed in or-
nithine delta-aminotransferase (OAT) deficiency [75,76]
(Figure 3). This is in line with a previous observation of
two patients with HHH syndrome, in whom urinarycreatine excretion was normalized by citrulline and argin-
ine but not by ornithine supplementation [21].
Since ORC1 is highly expressed in the brain and in par-
ticular in astrocytes, one could speculate that an 7absent
or dysfunctional protein may affects the metabolism of
neurons and of glial cells. Hyperammonemia has a toxic
effect on the astrocytes, causing mitochondrial dys-
function, cellular swelling and a change in cellular bio-
energetics [77]. Moreover, Braissant et al. [78] have shown
through in vitro experiments with reaggregated mixed
brain cells (neurons, astrocytes, oligodendrocytes and
microglia) primary cultures, impaired axonal growth and
abnormal localization and phosphorylation of the inter-
mediate neurofilament M-protein after ammonia expo-
sure. Addition of creatine to the media seems to protect
against this effect of ammonia on the neural cytoskeleton;
this protective effect depends on the presence of glial cells
and cannot be observed in neuron enriched cell cultures
(78). These findings suggest that in ORC1 deficiency
AGAT inhibition due to high ornithine levels reduces the
endogenous creatine production in cerebrum and cerebel-
lum and thus renders the brain more vulnerable to a local
increase of ammonia [78].
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thine and homocitrulline levels can cause protein and
lipid oxidation and may negatively interfere in oxidative
phosphorylation and Krebs cycle function of the rat
brain, with secondary oxidative stress [79,80]. Impair-
ment of brain bioenergetics and the oxidative damage
induced by these metabolites may possibly contribute to
the neurological symptoms affecting patients with HHH
syndrome.
Molecular genetics
HHH syndrome is a genetic autosomal recessive disease
caused by mutations in the SLC25A15 (solute carrier
family 25, member 15) gene [37]. This gene maps on
chromosome 13q14.11, spans about 23 kb and contains 7
exons encoding for the isoform 1 of the ornithine carrier
ORC1, a member of the mitochondrial carrier family [65].
The open reading frame is encoded by exons 2 through 7
[53]. Exon 1 encodes part of the 5’UTR. The normal pro-
duct of SLC25A15 gene is a 301 amino acid protein com-
posed, like other mitochondrial carriers, of six α-helices
that traverse the inner mitochondrial membrane with the
C- and N-termini exposed to the cytosolic side of the
membrane. ORC1 shows a tripartite structure with three
similar domains each with two transmembrane helices
connected by a long hydrophilic matrix loop [65]. There is
experimental evidence for the direct involvement of the
ORC1 residues E77, R179 and E180 in substrate binding,
whereas W224 and R275 seem to be important in trig-
gering the substrate-induced conformational changes that
leads to substrate translocation; N74 and N78 residues are
part of the substrate binding pocket [81] (Figure 4).
Several SLC25A15 mutations have been associated
with the clinical phenotype of the HHH syndrome. FromFigure 4 Human ORC1 homology model. Left panel shows the ORCI mo
substrate-binding site containing L- ornithine. The central panel shows the
model viewed as in the left panel but displayed with residues close to the bin
the cytosolic side in green and residues close to the substrate exit/entrance o
viewed from the membrane side with the color scheme as in the central pan1999 to 2014, 35 mutations have been identified: 18 mis-
sense mutations, 7 small insertion, 2 small deletions, 4 non-
sense mutations, 1 gross deletion, 1 micro-rearrangement,
1 intronic rearrangement (Table 1). All mutations occurred
in the coding region. Two common mutations, p.F188del
and p.R179*, are reported. The first accounts for about 30%
of patients with the HHH syndrome and it is characteristic
(but not exclusive) of patients of French-Canadian descent
because of a founder effect [38]. The second mutation
(15% of HHH patients) appears to be prevalent in pa-
tients of Japanese and Middle Eastern origin [27,47,57].
The functional effects of some SLC25A15 mutations on
substrate transport have been investigated using in vitro cell
culture and liposome reconstitution studies [53,57,68], re-
vealing that some SLC25A15 missense and nonsense muta-
tions (p.T32R, p.F188del, p.G190D, p.M273K, p.T272I,
p.G113C, p.L71Q and p.L283F) cause reduced transport
activity while others (p.G220R, p.R179*, p.G27R, p.R275Q
and R275*) completely abolish the function. Interestingly,
some patients with null SLC25A15 alleles did not show
neonatal hyperammonemia [57].
The 18 pathogenic missense mutations alter residues
phylogenetically conserved in the wild-type protein, which
may reflect that they have specific important roles for
function. However, the majority of the single-residue mu-
tations causing the HHH syndrome are non-conservative
substitutions that in many cases introduce a change in the
charge of amino acid side chain (p.A15E, p.G27R, p.G27E,
p.T32R, p.M37R, p.P126R, p.E180K, p.G190D, p.G220R,
p.M273K, p.R275G and p.R275Q) [22,37,57], prolines
(p.L193P and p.A264P) or residues with different side
chain size or polarity (p.A15V, p.G113C, p.G216S, p.T272I,
p.L71Q, p.F188L and p.L283F) [57,60], that alter the pro-
tein structure and function. Missense mutations can bedel, created as dcflbed in [80], viewedfroni the cytoplasnijc side ith the
location of the mutations causing the H H H syndrome in the ORC1
ding site colored in cyan, residues close to the substrate exit/entrance on
n the matrix side in magenta. The right panel shows the ORC1 model.
el.
Table 2 Biochemical data (mean ± SD, range, and number
of patients) detected in plasma of HHH syndrome
patients at diagnosis
Metabolites HHH patients Reference value
Ammonia 215 ± 279 (18–2300) n = 93 <55
Ornithine 575 ± 265 (216–1915) n = 96 30-110
Citrulline 26 ± 14 (1–57) n = 21 10-52
Glutamine 1149 ± 592 (447–3688) n = 43 333-809
Arginine 66 ± 26 (27–126) n = 22 20-112
Lysine 178 ± 177 (35–858) n = 26 80-257
Values are expressed as μmol/L.
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[81], which is based on the structure of the carboxyatracty-
loside inhibited bovine ADP/ATP carrier (PDB ID 1OKC),
to display the location of each mutation (Figure 4). In a
simple analysis, the mutations may be divided into three
groups depending on their location in the model: residues
close to the proposed binding site, residues close to the
substrate entrance/exit on the cytosolic side and residues
close to the substrate exit/entrance on the matrix side. The
majority of the HHH syndrome mutations are found in
residues that have side chains protruding into the internal
pore of ORC1 where the substrate is translocated, sug-
gesting that these mutations could interfere with substrate
translocation. Mutations located in residues of the sub-
strate binding site p.E180K, p.R275G and p.R275Q are pre-
sumably directly deleterious to substrate binding and other
mutations in proximity, such as p.G27R, p.G27E, p.T272I
and p.G113C, probably have an effect in deforming the
substrate-binding pocket. Mutations on the cytosolic side,
such as p.F188L, p.G190D, p.G216S and p.G220R, could
interfere with the substrate entering or exiting its binding
site, or with the closing/opening of the substrate-binding
cavity towards the cytosol. A similar explanation could be
given for the effect of p.T32R and p.A264P mutations that
interfere with the closing/opening of the substrate-binding
cavity but on the matrix side. The residues A15, M37, L71,
P126, L193 and M273 have side chains on the external
surface of ORC1 and therefore these mutations cannot
directly obstruct substrate translocation. Instead these
mutations may indirectly impair function, probably by
causing local perturbations in the ORC1 structure, e.g., the
proline of the p.P126R mutation is located in one of the sig-
nature motifs that are highly conserved in all mitochondrial
carriers and is likely to be crucial for the structure and con-
formational changes during substrate translocation [72].
Diagnosis
Biochemical profile
The metabolic triad of hyperammonemia, hyperornithine-
mia, and urinary excretion of homocitrulline establishes the
diagnosis of HHH syndrome. However, some patients may
present with an incomplete biochemical phenotype. The
biochemical data in individuals with HHH syndrome at
the time of diagnosis are summarized in Table 2 and in
Additional file 1: Table S1. Of note, HHH syndrome is cha-
racterized by a lower degree of hyperammonemia if com-
pared with other UCDs [1] and plasma ammonia level
usually normalizes in response to pharmacological treatment.
Plasma concentration of ornithine can range from 216 to
1915 μmol/L (normal: 30–110 μmol/L). Despite protein-
restricted diet in combination with pharmacological treat-
ment, ornithine concentration in plasma remains elevated
with only a very few patients reported with normal levels
at long-term follow-up [2-4,15,48,56].Homocitrullinuria is a hallmark of the disease, how-
ever some patients may show absent or only minimal
excretion of homocitrulline in urine [50] (Additional
file 1: Table S1).
Similarly to other UCDs [1], plasma glutamine con-
centrations and urinary orotic acid may be elevated
(Additional file 1: Table S1). Occasional organic aciduria,
with increase excretion of Krebs Cycle intermediates
(succinate, citrate, fumaric, α-ketoglutaric) and lactate
was reported [50,52].
Study of intracellular mitochondrial transport of radiolabelled
14C-ornithine in cultured skin fibroblasts
The diagnosis of HHH syndrome may be confirmed by
the evaluation of cellular mitochondrial transport of
radiolabelled 14C-ornithine in cultured skin fibroblasts
[9]. Cultured fibroblasts from patients with null muta-
tions usually show an approximately 75%-80% reduction
in ornithine transport: this may suggest a potential role
of redundant transporters in achieving a residual trans-
port [37,69]. There is no correlation between ornithine
transport capacity, genotype and phenotype [37,53].
Other investigations
As detected by computer tomography (CT) scan and
magnetic resonance (MRI) studies, brain abnormalities
include mild cerebral and cerebellar atrophy [16,23,31,
27,57], white matter changes [4,57,59], subdural hematoma
[C. Dionisi-Vici, personal observation], cystic lesions and
calcifications [4], and diffuse brain edema, evident at ultra-
sound scan [35]. However, normal brain CT scan or MRI
findings were reported in several patients, mainly in those
who did not experience an overt hyperammonemic coma
[36,40,60]. Interestingly, multiple stroke-like lesions were
reported in a 4 year-old patient presenting irritability,
vomiting, highly elevated liver enzymes, hyperammonemia,
and coagulopathy [56].
Neurophysiologic studies show abnormal motor evoked
potentials affecting pyramidal tract of lower limbs, generally
without upper limb involvement [24,36]. Somatosensory
evoked potentials are normal; electroneuromyography can
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and may reveal signs of spinal anterior horn cells de-
generation [34].
Blood coagulation studies may be abnormal with
deficiency of factor VII, X, XI, and antithrombin
III [7,15,21,38,39,55-57].
Liver structural (light microscopy) and ultrastructural
changes (electron microscopy) are commonly observed
[7,9,26,40,57,82] and include vacuolated hepatocytes
with intracytoplasmic glycogen deposition, small nuclei,
dense chromatin, and fat droplets without fibrosis. At
electron microscopy, mitochondria appear abnormally
shaped and sized with lamellar cristal-like inclusions [11].
Differential diagnosis
Hyperammonemia
HHH syndrome enters in the differential diagnosis of any
patient presenting with hyperammonemia at any age. The
main causes of hyperammonemia associated with inborn
errors of metabolism include [1,83]: UCDs (they generally
present along with elevation in plasma ammonia concen-
tration, hyperglutaminemia and metabolic alkalosis); or-
ganic acidemias (they show in addition metabolic acidosis,
ketonuria and normal or reduced plasma glutamine levels);
fatty-acid oxidation defects (hyperammonemia is as-
sociated with hypoglycaemia, hypertransaminasemia, in-
crease of plasma creatine-phosphokinase levels); lysinuric
protein intolerance (characterized by low concentrations
of plasma ornithine, lysine, and arginine and persistent
urinary excretion of lysine, ornithine, and arginine);
hyperinsulinism-hyperammonemia syndrome (characte-
rized by severe hypoglycaemia); pyruvate carboxylase defi-
ciency (presenting with lactic acidosis and hypoglycaemia);
and the recently reported defect of mitochondrial carbonic
anhydrase VA (presenting with lactic acidosis, hypoglycae-
mia and a characteristic organic aciduria) [84].
A complete routine chemistry panel [i.e. blood ammo-
nia, glucose, lactate, liver function tests (including trans-
aminases, gamma-GT, coagulation, bilirubin, albumin)
creatine kinase, uric acid, arterial blood gases, and blood
cell counts, urinalysis], and metabolic investigations with
plasma amino acids, urine amino acids,organic acids and
orotic acid measurements allow the differential diagnosis.
Hyperornithinemia
Hyperornithinemia is also a characteristic feature of
OAT deficiency responsible for gyrate atrophy of the
choroid and retina (OMIM #258870) [85]. This disorder
is caused by defect in OAT gene, located at 10q26. The
fasting plasma ornithine in OAT deficiency ranges from
400 to 1400 μmol/L [85]. Initial symptoms include myopia
and night blindness, starting in early to mid-childhood;
patients then develop reduction of visual fields, posterior
subcapsular cataracts and abnormal electroretinogram[85]. The fundoscopic aspect of the chorioretinal atrophy
in gyrate atrophy is highly specific. Patients have generally
a normal cognitive level, although one large series suggests
an increased incidence of intellectual impairment [76]. A
few OAT patients experienced neonatal hyperammonemia
[86]. Interestingly, and similarly to some HHH patients,
they were all found to have normal plasma ornithine con-
centration at birth which progressively increased in the
following weeks when the diagnosis was fully defined [86].
Homocitrullinuria
Other conditions in which homocitrullinuria can be
observed should be listed in the differential diagnosis of
HHH syndrome. These include lysinuric protein intole-
rance (MIM# 222700) or OTC deficiency (MIM# 311250),
which can present in some cases with low quantity of
homocitrulline in urine [87,88]. Furthermore, canned food
or heated milk products may represent a source of detect-
able homocitrulline in urine [88].
Neurologic findings
In patients with early childhood onset of gait abnorma-
lities and spasticity, the differential diagnosis includes
cerebral palsies and inherited spastic paraplegias. Interes-
tingly among the inherited disorders of the UC, HHH syn-
drome and argininemia share the peculiar neurological
feature of pyramidal dysfunction [1,88,89].
Newborn screening
In some countries, like United States and Canada, HHH
syndrome is included in the disease panel of expanded
newborn screening programs. However, it may be missed
on newborn screening because some affected neonates
may not show in the first days of life elevated plasma
ornithine levels that can be detected by tandem mass
spectroscopy [90]. Authors suggested that the typical rise
of plasma ornithine levels occurs after the first few days
of life when blood samples for newborn screening are
obtained.
Genetic diagnosis
Genetic testing is the gold standard to confirm the diag-
nosis. The SLC25A15 gene was cloned in 1999 and a
common F188del mutation in French Canadian patients
was identified [37]. Genetic analysis does not have a
prognostic value since even in the same family and with
the same mutation the phenotype can be quite variable.
Sequence analysis is performed first, followed by dele-
tion/duplication analysis if only one or no mutant
SLC25A15 alleles are detected. The gold standard for
prenatal diagnosis in couples of known genotype is mu-
tation analysis. Before the discovery of the molecular
basis of HHH syndrome, prenatal diagnosis has been
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cultured amniotic fluid cells [35,41].Management
Acute treatment is similar to other UCDs [1]. Protein in-
take must be stopped for 24 h and intravenous glucose
in combination with first-line medications must be
started. Arginine (and/or citrulline) must be adminis-
tered to replace the missing UC intermediates and to
allow protein synthesis. Ammonia scavengers as sodium
benzoate and sodium phenylbutyrateare used for bypas-
sing the UC block. Long-term treatment is based on a
low-protein diet supplemented with citrulline or arginine;
ornithine supplementation has been tried in the past
with contradictory results [4,18,21,24,25,31] in the
attempt to correct ornithine depletion in the mito-
chondria, however its use is not recommended. Protein
restriction may be combined with sodium benzoate or
sodium phenylbutyrate. If plasma creatine levels are
low, creatine supplementation should be instituted
[1,44,74]. Citrulline supplementation has been shown to
allow better metabolic control and to avoid secondary
creatine deficiency [21]. The retrospective review of the
literature provided information on treatment modalities
in HHH patients. All were treated with low protein diet,
22% with protein restriction alone. Thirty per cent of
patients received arginine supplementation, 22% citrul-
line and 10% ornithine; 36% were treated with ammonia
scavengers, (21% benzoate, 12% phenylbutyrate, and 3%
combined benzoate and phenylbutyrate). To our know-
ledge, liver transplantation was done only in one HHH
patient with severe metabolic derangement [54]. The
main parameters to be monitored at follow-up are simi-
lar to other UCDs [1], and include plasma ammonia,
plasma aminoacids and urinary orotic acid.Prognosis
Prognosis is highly variable ranging from mild neu-
rological involvement to a severely disabling disease
(Table 1). Out of the 106 patients with a known vital
status (median age 14 years, range 1 month – 57 years),
7 patients died, representing an overall mortality rate
of the 6,6%. An appropriate management with protein
restriction diet, supplements and ammonia scavengers
allows almost normal life duration. Treated patients
are usually metabolically stable and do not experience
relapses of hyperammonemia [38]. Hepatic signs re-
solve rapidly with treatment and long-term hepatic
function is normal [52]. Chronic therapy prevents
hyperammonemia and liver disease but does not affect
the spastic paraparesis [21,22,38]. Successful pregnan-
cies have been reported in HHH syndrome female pa-
tients [4,7,29].Unresolved questions
Although the disease responds well to treatment with low
risk of relapse of hyperammonemia [38], slowly progres-
sive pyramidal signs characterize the chronic course, as
also seen in argininemia [89]. However, the mechanism(s)
of pyramidal dysfunction in HHH syndrome still remains
to be elucidated. Creatine deficiency may contribute to
the pathogenetic mechanism of the syndrome, as creatine
is relevant for mitochondrial energy metabolism, re-
gulation of glycolysis, proteins synthesis, membrane sta-
bilization and neuromodulation [77,78,85]. This could be
in line with the finding of abnormally shaped mitochondria
at electron microscopy studies in skin fibroblasts, hepato-
cytes and muscle biopsy from HHH syndrome patients
[11,23,82]. Furthermore, a mitochondrial dysfunction has
been recently related to the effects of ornithine and homo-
citrulline in causing oxidative stress and disturbed mito-
chondrial homeostasis [79,80].
A further mechanism that can be involved in the patho-
physiology of HHH syndrome is related to polyamines
metabolism. Shimizu and colleagues reported increased
total and fractional (putrescine, cadaverine, spermine,
spermidine) polyamines in one HHH syndrome patient
[30]. Indeed, the clinical similarities between HHH syn-
drome and argininemia, which has been associated to an
abnormal polyamine metabolism [91,92], may suggest a
common pathogenetic mechanism causing pyramidal
dysfunction.
Overall, the pathogenesis of HHH syndrome is com-
plex and not completely understood. It is likely that
different mechanisms, including the impact of low
mitochondrial ornithine on UC flux, the presence of
hyperammonemic crises and the disturbance of other
pathways in major organs play a role in determining the
heterogeneous clinical presentation of ORC1 deficiency.
In addition, as molecular studies failed to disclose
a correlation between type of mutations or ornithine
transport capacity and disease severity, an effect of
genetic modifiers, such as ORC genes redundancy, seems
to be likely, but further studies are certainly needed to
clarify this point.
Interestingly, there is a report describing hyperammone-
mic encephalopathy in two consanguineous weanling foals
presenting postweaning with anorexia, abnormal behaviour,
unthriftiness, and poor growth [93]. Hyperammonemia was
associated with increased transaminases, abnormal coagula-
tion, and mild hyperbilirubinemia. The animal presented
with severe neurologic abnormalities, including circling,
bilateral forelimb and hindlimb ataxia, and dementia.
Biochemical investigations revealed an aminoacid profile
consistent with HHH syndrome with elevated serum orni-
thine and glutamine, homocitrullinuria and orotic aciduria,
highlighting the strong similarities between the human dis-
ease and this spontaneous animal model.
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In this article, we have retrospectively reviewed the clinical
and metabolic profiles of all reported HHH syndrome pa-
tients. The combination of peculiar clinical features and the
biochemical triad of hyperammonemia, persistent hyperor-
nithinemia, and urinary excretion of homocitrulline, allows
the diagnosis of HHH syndrome. Encephalopathy, coagulop-
athy and liver disease are common acute features, whereas
pyramidal dysfunction and cognitive disabilities typically
characterize the chronic course of the disease. The clinical
phenotype is extremely variable and its severity does not
correlate with the genotype or with recorded ammonium/
ornhitine plasma levels. The pathophysiological mechanisms
underlying HHH syndrome have not been fully elucidated
yet, but they seem to include features common to both pri-
mary UCDs as well as to mitochondrial disorders.
Additional file
Additional file 1: Table S1. The table summarizes the relevant laboratory
findings at diagnosis in 111 patients with HHH syndrome. Values of
ammonia and glutamine are expressed as μmol/L. Urinary orotate and
homocitrulline (when possible) are expressed as μmol/mmol creatinine.
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